Pneumococcal ImmunizationNCT07809113
PCV21 Acceptance in Adults ≥50 Years and Caregivers in Panama
An observational study of Pneumococcal Immunization, run by Endpoints Site Network at 1 site in Panama.
Trial summary
This study will look at what adults age 50 years and older in Panama know, think, and do about pneumococcal vaccination, including the 21-valent pneumococcal conjugate vaccine (PCV21). Pneumococcal disease can cause pneumonia and other serious infections, and older adults may be at higher risk of severe illness. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pneumococcal Immunization
- How many people
- 600 participants
- Where
- 1 sitePanama
- Study dates
- 1 Feb 2027to 31 Dec 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will include adults aged 50 years and older in Panama who receive care through public or private health care facilities. Participants will be recruited from urban, semi-urban, and rural settings to reflect the demographic, geographic, and socioeconomic diversity of the adult population in Panama.
Who may be able to join
- Age 50 years or older.
- Cohort A: 50-64 years.
- Cohort B: 65 years or older.
- Resident of Panama, including urban, semi-urban, or rural areas.
- Has access to medical care through the public or private health care system.
- Able and willing to provide signed informed consent.
Show all 11Show fewer
- Caregivers - Cohort B only
- Age 18 years or older.
- Identified as the caregiver of a Cohort B older adult.
- Has regular cohabitation or contact with the older adult, defined as at least once per week.
- Able and willing to provide signed informed consent.
Who cannot join
- Older adults - all cohorts
- Cognitive impairment that prevents the participant from providing informed consent.
- Does not speak Spanish and no interpreter is available.
- Caregivers - Cohort B only
- Professional caregiver with no personal relationship to the older adult.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Panama1 site
CEVAXIN
Panama City, Provincia de Panamá
Gabrielle Britton, PhD, gabrielle.britton@cevaxin.com
About this study
Official title: Intergenerational Determinants of PCV21 Acceptance in Adults ≥50 Years in Panama: Knowledge, Attitudes, and Practices in Older Adults and Their Caregivers
This study will look at what adults age 50 years and older in Panama know, think, and do about pneumococcal vaccination, including the 21-valent pneumococcal conjugate vaccine (PCV21). Pneumococcal disease can cause pneumonia and other serious infections, and older adults may be at higher risk of severe illness. The study will help researchers understand what supports or prevents vaccine acceptance in this population.
The study will include two groups. Group A will include adults 50 to 64 years of age. Group B will include adults 65 years of age or older and a caregiver chosen by the older adult. A caregiver may be a family member or another person who regularly helps or supports the older adult. Researchers will study whether the caregiver's views about vaccines are related to the older adult's intention to receive PCV21.
Read more
Participants will complete a one-time survey about pneumococcal disease, vaccines, vaccination history, health information sources, trust in vaccines, barriers to vaccination, and factors that may make vaccination easier. Surveys may be completed on paper with help from study staff or digitally using a tablet or smartphone. The survey is expected to take about 10 to 15 minutes. For older adults and caregivers in Group B, each person will complete their own survey separately so that one person's answers do not influence the other's answers.
This is an observational study. No vaccine, medicine, or study product will be given as part of the study. Taking part involves answering survey questions only. The study will recruit participants from public and private health care facilities, including at least one rural or semi-urban site, to better reflect the diversity of adults in Panama.
The information from this study may help health care providers, public health teams, and community organizations design clearer and more useful communication about pneumococcal vaccination for adults and their caregivers. The results may also support future recommendations for adult vaccination programs in Panama and similar settings.
- Conditions
- Pneumococcal Immunization
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COHORT A | Adults 50-64 years | |
| COHORT B | Adults ≥65 years + caregiver (dyads) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Level of knowledge, attitudes, and practices regarding PCV21 vaccination among adults aged 50 years and older in Panama
Knowledge, attitudes, and practices regarding pneumococcal disease and PCV21 vaccination will be assessed using a structured KAP survey. Survey domains include knowledge of pneumococcal disease and available vaccines, attitudes toward vaccination and PCV21, vaccine confidence, perceived risk, prior vaccination practices, preventive care behaviors, and sources of health information. Results will be summarized overall and by cohort.
Measured: At enrollment / single study visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2026
- Study start1 Feb 2027 (estimated)
- Primary completion30 Sep 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pneumococcal ImmunizationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Endpoints Site Network
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Ana G Lucas, MD, Principal investigator, Endpoints
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07809113
- Sponsor's protocol ID
- MISP 104141
- Other IDs
- MISP 104141
- Status last verified
- Sep 2026
- First submitted
- 2 Sep 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided